정맥혈전색전증(VTE) 시장 규모 및 동향 : 역학, 질병 관리, 파이프라인 분석, 경쟁사 평가, 미충족 수요, 임상시험 전략, 예측(-2032년)

Venous Thromboembolism Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast to 2032

US $ 14,995 ￦ 21,172,000

Zip (Single User License)

ZIP파일 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 29,990 ￦ 42,345,000

Zip (Site License)

ZIP파일 보고서를 동일 기업의 한 부서에서 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 44,985 ￦ 63,518,000

Zip (Global License)

ZIP파일 보고서를 동일 기업(해외)의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

미국, 프랑스, 독일, 이탈리아, 스페인, 영국, 일본 등 주요 7개 시장(미국, 프랑스, 독일, 이탈리아, 스페인, 영국, 일본)의 정맥혈전색전증(VTE) 시장 규모는 2022년 약 35억 7,000만 달러에서 예측 기간 말에는 46억 2,000만 달러에 달하고, CAGR 2.6%로 성장할 것으로 예상됩니다. 이러한 소폭의 성장은 예측 기간 동안 발생하는 신규 경구용 항응고제(NOAC)의 특허 만료에 따른 제네릭 의약품의 침식 등에 기인합니다.

이 보고서는 7개 주요 시장의 정맥혈전색전증(VTE, Venous Thromboembolism) 시장을 조사 분석하여 수익 예측, 파이프라인 분석, 경쟁 구도 등의 정보를 제공합니다.

목차

제1장 정맥혈전 색전증(VTE) : 주요 요약

• VTE 시장은 2022년부터 2032년까지 최소한의 성장에 그칠 것
• 기업들은 제11인자 억제제에 대한 임상시험 개발에 집중
• 암 또는 신장 장애가있는 환자를 위한 최적의 치료 전략이 필요
• Abelacimab은 예측 기간 동안 매출에 적당히 기여할 것
• 의사들은 어떻게 생각하는가?

제2장 서론

• 촉매
• 관련 보고서
• 향후 보고서

제3장 질환 개요

• 병인학과 병태생리학

제4장 역학

• 질환의 배경
• 위험 요인과 병존 질환
• 세계의 과거 동향
• 주요 7개 시장 예측 방법
• 정맥혈전 색전증(VTE) 역학 예측(2022년-2032년)
• 논고

제5장 질병 관리

• 진단 및 치료 개요
• 질병 관리에 관한 KOL 인사이트

제6장 경쟁 평가

• 개요

제7장 미충족 요구와 기회 평가

• 개요
• 출혈 리스크 경감
• 암 환자에 대한 최적의 치료
• 신장 장애 및 신부전 환자에 대한 최적의 치료
• 비경구 요법에 수반하는 합병증
• 의사와 환자 교육 개선

제8장 연구개발 전략

• 개요
• 임상시험 설계

제9장 파이프라인 평가

• 개요
• 임상 개발 중인 유망한 약품

제10장 파이프라인 평가 분석

• 개요
• 경쟁 평가

제11장 현재와 향후 기업

• 개요
• 거래 결정 동향

제12장 시장 전망

• 세계 시장
• 미국
• 유럽 5개국
• 일본

제13장 부록

LSH

영문 목차

영문목차

Abstract

This report covers the 7MM (US, France, Germany, Italy, Spain, UK, Japan) and provides an Excel-based forecast model for the Venous Thromboembolism (VTE) market through 2032.

According to GlobalData estimates, 2022 base year sales within the VTE market are approximately $3.57 billion across the 7MM detailed in this report. The US is the most significant contributor to that revenue, accounting for 80.8% of sales. This can be attributed to the large size of the VTE patient population in the US as well as the higher overall price of drugs as compared to the 5EU and Japan. GlobalData estimates that the VTE market will grow at a compound annual growth rate (CAGR) of 2.6% to reach $4.62 billion by the end of the forecast period. This minimal growth is due to the generic erosion that will occur as patents for novel oral anticoagulants (NOACs) expire throughout the forecast period. Furthermore, although there is one late-stage pipeline therapy that is expected to launch in the US and 5EU during the forecast period, the drug will only capture a small share of the market due to its high cost, subcutaneous method of administration, long half-life, and lack of strong clinical trial data.

Report deliverables include a Pdf and an Excel-based forecast model

Forecast includes the 7 major markets (7MM)

Forecast covers the period 2022-2032.

• 2022 base year sales within the VTE market are approximately $3.57 billion across the 7MM detailed in this report. GlobalData estimates that the VTE market will grow at a compound annual growth rate (CAGR) of 2.6% to reach $4.62 billion by the end of the forecast period.
• This minimal growth is due to the generic erosion that will occur as patents for novel oral anticoagulants (NOACs) expire throughout the forecast period as well as only one late-stage pipeline therapy that will only capture a small share of the market due to its high cost, subcutaneous method of administration, and lack of strong clinical trial data.

Scope

• Overview of VTE, including epidemiology, symptoms, diagnosis, and disease management.
• Annualized VTE therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2021 to 2031.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the VTE market.
• Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for VTE treatment and prophylaxis. The most promising candidates in late-stage development are profiled.
• Analysis of the current and future market competition in the 7MM VTE therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the 7MM obesity therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 7MM VTE therapeutics market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

Table of Contents

1 Venous Thromboembolism: Executive Summary

• 1.1 The VTE market will experience minimal growth between 2022 and 2032
• 1.2 Companies are focusing clinical trial development on factor XI inhibitors
• 1.3 Optimal treatment strategies for patients with cancer or renal impairment are needed
• 1.4 Abelacimab to contribute moderately to sales during the forecast period
• 1.5 What do physicians think?

2 Introduction

• 2.1 Catalyst
• 2.2 Related reports
• 2.3 Upcoming reports

3 Disease Overview

• 3.1 Etiology and pathophysiology

4 Epidemiology

• 4.1 Disease background
• 4.2 Risk factors and comorbidities
• 4.3 Global and historical trends
• 4.4 7MM forecast methodology
• 4.5 Epidemiological forecast for venous thromboembolism (VTE) (2022-32)
• 4.6 Discussion

5 Disease Management

• 5.1 Diagnosis and treatment overview
• 5.2 Key opinion leader insights on disease management

6 Competitive Assessment

• 6.1 Overview

7 Unmet Needs and Opportunity Assessment

• 7.1 Overview
• 7.2 Mitigating bleeding risk
• 7.3 Optimal treatment for cancer patients
• 7.4 Optimal treatment for patients with renal impairment and renal failure
• 7.5 Complications associated with parenteral therapies
• 7.6 Improved education among physicians and patients

8 R&D Strategies

• 8.1 Overview
• 8.2 Clinical trials design

9 Pipeline Assessment

• 9.1 Overview
• 9.2 Promising drugs in clinical development

10 Pipeline Valuation Analysis

• 10.1 Overview
• 10.2 Competitive assessment

11 Current and Future Players

• 11.1 Overview
• 11.2 Deal-making trends

12 Market Outlook

• 12.1 Global markets
• 12.2 US
• 12.3 5EU
• 12.4 Japan

13 Appendix

• 13.1 Bibliography
• 13.2 Abbreviations
• 13.3 Methodology
• 13.4 Primary research - key opinion leaders interviewed for this report
• 13.5 Primary research - prescriber survey
• 13.6 About the Authors
• Contact Us

관련자료